RZ402 for Diabetic Macular Edema

"Despite the fact that there is limited evidence to suggest its efficacy, Group 1 - 50 mg RZ402 has been tentatively rated a 2 out of 3 for safety due to some prior data demonstrating its security."

"According to the study's requirements, only individuals between 18 and 75 years of age can participate. There are 7 studies that solely involve youth while 110 focus on elderly patients."

"Affirmative. Clinicaltrials.gov data display that this investigation, which was first posted on February 1st 2023, is currently recruiting patients. The research requires 100 individuals to be accepted from a single medical centre."

"According to clinicaltrials.gov, the medical research program is currently recruiting participants with a posted date of February 1st 2023 and an updated timestamp from January 31st 2023."

"This 16-week trial's primary aim is to observe changes in Central Subfield Thickness. Secondary outcomes include a shift from baseline in the Diabetic Retinopathy Severity Score (DRSS) between placebo and treatment groups, along with Repeat-dose Cmax and T1/2 of RZ402. DRSS ranges from 10 to 90, where higher numbers indicate worse results."

"This trial is recruiting 100 individuals with diabetic macular edema, aged 18 to 75. Candidates must demonstrate: a diagnosis of Type 1 or 2 diabetes mellitus; consistent blood glucose levels; mild-to-moderate nonproliferative diabetic retinopathy (NPDR); spectral domain optical coherence tomography foveal central subfield thickness reading ≥320 µm at screening; best corrected visual acuity ETDRS letter score ≤78 letters at 4 meters during the initial evaluation; clear media clarity, pupil dilation and cooperation necessary for adequate clinic evaluations, OCT images, and fundus photographs throughout testing; and an"